10 results on '"Natalia A. Tsareva"'
Search Results
2. Potential for the Lung Recruitment and the Risk of Lung Overdistension During 21 Days of Mechanical Ventilation in Patients With COVID-19 After Noninvasive Ventilation Failure: the COVID-VENT Observational Trial
- Author
-
M. E Politov, Andrey Yavorovskiy, Natalia V. Trushenko, Andrey I. Yaroshetskiy, Anna P. Krasnoshchekova, Yury D. Sorokin, Natalia A. Tsareva, Pavel Nogtev, Sergey Avdeev, Victoria G. Beresneva, Zamira M. Merzhoeva, Vasily D. Konanykhin, and Irina A. Mandel
- Subjects
Mechanical ventilation ,Lung ,Coronavirus disease 2019 (COVID-19) ,Observational Trial ,business.industry ,medicine.medical_treatment ,respiratory system ,Lung recruitment ,medicine.anatomical_structure ,Anesthesia ,Medicine ,Noninvasive ventilation ,In patient ,business - Abstract
Background: Data on the lung respiratory mechanics and gas exchange in the time course of COVID-19-associated respiratory failure is limited. This study aimed to explore respiratory mechanics and gas exchange, the lung recruitability and risk of overdistension during the time course of mechanical ventilation. Methods: This was a prospective observational study in critically ill mechanically ventilated patients (n=116) with COVID-19 admitted into Intensive Care Units of Sechenov University. The primary endpoints were: «optimum» positive end-expiratory pressure (PEEP) level balanced between the lowest driving pressure and the highest SpO2 and number of patients with recruitable lung on Days 1 and 7 of mechanical ventilation. We measured driving pressure at different levels of PEEP (14, 12, 10 and 8 cmH2O) with preset tidal volume, and with the increase of tidal volume by 100 ml and 200 ml at preset PEEP level, and calculated static respiratory system compliance (CRS), PaO2/FiO2, alveolar dead space and ventilatory ratio on Days 1, 3, 5, 7, 10, 14 and 21.Results: The «optimum» PEEP levels on Day 1 were 11.0 (10.0-12.8) cmH2O and 10.0 (9.0-12.0) cmH2O on Day 7. Positive response to recruitment was observed on Day 1 in 27.6% and on Day 7 in 9.2% of patients. PEEP increase from 10 to 14 cmH2O and VT increase by 100 and 200 ml led to a significant decrease in CRS from Day 1 to Day 14 (p2/FiO2 was 105.5 (76.2-141.7) mmHg in non-survivors on Day 1 and 136.6 (106.7-160.8) in survivors (p=0.002). In survivors, PaO2/FiO2 rose on Day 3 (p=0.008) and then between Days 7 and 10 (p=0.046). Conclusion: Lung recruitability was low in COVID-19 and decreased during the course of the disease, but lung overdistension occurred at «intermediate» PEEP and VT levels. In survivors gas exchange improvements after Day 7 mismatched CRS.Trial registration: ClinicalTrials.gov, NCT04445961. Registered 24 June 2020 - Retrospectively registered, http://https://clinicaltrials.gov/ct2/show/NCT04445961?cond=COVID-19&cntry=RU&city=Moscow&draw=3&rank=23
- Published
- 2021
3. Using TAPSE (tricuspid annular plane systolic excursion) as a predictor of poor prognosis of COVID-19: is it enough?
- Author
-
Natalia V. Trushenko, Galina Nekludova, Sergey Avdeev, Kirill Ataman, and Natalia A. Tsareva
- Subjects
TAPSE ,Microbiology (medical) ,medicine.medical_specialty ,Poor prognosis ,2019-20 coronavirus outbreak ,Critical Care ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Infectious and parasitic diseases ,RC109-216 ,Cardiovascular ,Article ,Internal medicine ,medicine ,Humans ,Tricuspid valve ,SARS-CoV-2 ,Plane (geometry) ,business.industry ,Excursion ,COVID-19 ,General Medicine ,Prognosis ,Infectious Diseases ,medicine.anatomical_structure ,Echocardiography ,Cardiology ,Tricuspid Valve ,business - Abstract
Background This systematic review and meta-analysis aimed to assess the association between the tricuspid annular plane systolic excursion (TAPSE) measured by echocardiography and mortality in COVID-19. Methods We performed a systematic literature search using PubMed, Embase, and Scopus databases with keywords "COVID-19" OR "SARS-CoV-2" OR “2019-nCoV” AND “Tricuspid annular plane systolic excursion” OR “TAPSE” up until 20 January 2021. The main outcome was mortality; the effect estimate was reported in hazard ratio (HR) which was pooled from the unadjusted and adjusted effect estimate retrieved from the included studies. Mean difference of the TAPSE (in mm) between non-survivors and survivors were pooled. Results There were 641 patients from 7 studies included in this systematic review and meta-analysis. TAPSE was lower in non-survivors compared to survivors (mean difference -3.74 [-5.22, -2.26], p
- Published
- 2021
4. Recombinant tissue plasminogen activator treatment for COVID-19 associated ARDS and acute cor pulmonale
- Author
-
Zamira M. Merzhoeva, Djuro Kosanovic, Andrey I. Yaroshetskiy, Galina Nekludova, Natalia V. Trushenko, Natalia A. Tsareva, Sergey Avdeev, and Ralph T. Schermuly
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,ARDS ,Coronavirus disease 2019 (COVID-19) ,Acute cor pulmonale ,medicine.medical_treatment ,030106 microbiology ,Hemodynamics ,Case Report ,lcsh:Infectious and parasitic diseases ,03 medical and health sciences ,0302 clinical medicine ,Recombinant tissue plasminogen activator ,Internal medicine ,medicine ,lcsh:RC109-216 ,030212 general & internal medicine ,Respiratory system ,business.industry ,SARS-CoV-2 ,COVID-19 ,Thrombolysis ,General Medicine ,medicine.disease ,respiratory tract diseases ,Infectious Diseases ,Coagulation ,Cardiology ,medicine.symptom ,business ,Hypercapnia - Abstract
Highlights • COVID-19 may be characterized by an abnormal coagulation process and microvascular thrombosis of the lung vasculature. • COVID-19 may also be linked with acute respiratory distress syndrome (ARDS) and acute cor pulmonale (ACP). • We confirmed the development of ACP in a patient suffering from COVID-19. • We treated our patient with systemic thrombolysis and this resulted in a marked improvement in hemodynamics. • In addition, there was a significant reduction in hypercapnia, alveolar dead space, and ventilatory ratio., Existing literature highlights the fact that patients with COVID-19 exhibit alterations in the coagulation process and are associated with respiratory and cardiovascular diseases, including acute respiratory distress syndrome and acute cor pulmonale. In this report, we describe the effects of systemic thrombolysis on acute cor pulmonale in a patient suffering from COVID-19. We demonstrated that systemic thrombolysis successfully improved the hemodynamics of our patient and resulted in a prominent reduction in hypercapnia, alveolar dead space, and ventilatory ratio.
- Published
- 2021
- Full Text
- View/download PDF
5. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension. final safety data from the EXPERT registry
- Author
-
Hossein-Ardeschir Ghofrani, Miguel-Angel Gomez Sanchez, Marc Humbert, David Pittrow, Gérald Simonneau, Henning Gall, Ekkehard Grünig, Hans Klose, Michael Halank, David Langleben, Repke J. Snijder, Pilar Escribano Subias, Lisa M. Mielniczuk, Tobias J. Lange, Jean-Luc Vachiéry, Hubert Wirtz, Douglas S. Helmersen, Iraklis Tsangaris, Joan A. Barberá, Joanna Pepke-Zaba, Anco Boonstra, Stephan Rosenkranz, Silvia Ulrich, Regina Steringer-Mascherbauer, Marion Delcroix, Pavel Jansa, Iveta Šimková, George Giannakoulas, Jens Klotsche, Evgenia Williams, Christian Meier, Marius M. Hoeper, Jorge Caneva, Graciela Tuhay, Mirta Diez, Maria Lujan Talavera, Adriana Acosta, Norberto Vulcano, Martin Bosio, Lorena Maldonado, Sabino Deleo, Luciano Melatini, Anne Keogh, Eugene Kotlyar, John Feenstra, Nathan Dwyer, Heath Adams, Wendy Stevens, Peter Steele, Susanna Proudman, Robert Minson, Glenn Reeves, Melanie Lavender, Benjamin Ng, Michele Mackenzie, Lisa Barry, Margarethe Gruenberger, Charlotte Huber, Irene Lang, Ioana Tilea, Roela Sadushi-Kolici, Judith Löffler-Ragg, Lisa-Theresa Feistmantl, Patrick Evrard, Renaud Louis, Julien Guiot, Marco Naldi, Michel De Pauw, Sanjay Mehta, Rafael Conde Camacho, Patricia Parada Tovar, Alejandro Londoño, Felipe Campo, Paula Garcia, Camila Lema, Mauricio Orozco-Levi, William Martinez, Juan Esteban Gomez, Jens Erik Nielsen-Kudsk, Soren Mellemkjaer, Ly Anton, Alan Altraja, Tapani Vihinen, Tuija Vasankari, Olivier Sitbon, Vincent Cottin, Laurent Têtu, Elise Noël-Savina, Nicole Shearman, Susanne Tayler, Ilona Olzik, Christine Kulka, Jan Grimminger, Marcel Simon, Anna Nolde, Tim Oqueka, Lars Harbaum, Benjamin Egenlauf, Ralf Ewert, Christian Schulz, Sabine Regotta, Tilmann Kramer, Susanne Knoop-Busch, Felix Gerhardt, Stavros Konstantinides, Georgia Pitsiou, Ioannis Stanopoulos, Evdokia Sourla, Sofia Mouratoglou, Haralambos Karvounis, Athanasios Pappas, Dimitrios Georgopoulos, Michail Fanaridis, Ioanna Mitrouska, Lampros Michalis, Konstantinos Pappas, Anna Kotsia, Sean Gaine, Carmine Dario Vizza, Giovanna Manzi, Roberto Poscia, Roberto Badagliacca, Piergiuseppe Agostoni, Noemi Bruno, Stefania Farina, Michele D'Alto, Paola Argiento, Anna Correra, Giovanni Maria Di Marco, Chiara Cresci, Vieri Vannucchi, Elena Torricelli, Alessio Garcea, Alberto Pesci, Luca Sardella, Giuseppe Paciocco, Federico Pane, Andrea Maria D'Armini, Maurizio Pin, Valentina Grazioli, Giulia Massola, Antonio Sciortino, Renato Prediletto, Carolina Bauleo, Edoardo Airò, Rudina Ndreu, Ivana Pavlickova, Claudio Lunardi, Massimiliano Mulè, Silvia Farruggio, Serena Costa, Giuseppe Galgano, Mario Petruzzi, Anna De Luca, Francesco Lombardi, Loris Roncon, Luca Conte, Claudio Picariello, Gil Wirtz, Myriam Alexandre, A. Vonk-Noordegraaf, H. Boogaard, J. Mager, H. Reesink, Leon M. van den Toorn, Karin Boomars, Arne K. Andreassen, Graça Castro, Gonçalves Tania, Rui Baptista, António Marinho, Teresa Shiang, Ana Oliveira, Daniel Coutinho, Joana Sousa, Maria José Loureiro, Débora Repolho, Susana Maria Martins Jesus, Marta Capinha, João Agostinho, Tania Cardoso, Andreia Rocha, Mafalda Espinha, Kyundyul Ivanovich Ivanov, Dalyana Eduardovna Alexeeva, Marina Vadimovna Batalina, Daria Viktorovna Hegya, Tatyana Nikolaevna Zvereva, Sergey Nikolaevich Avdeev, Natalia Anatolievna Tsareva, Albert Sarvatovich Galyavich, Bykov Aleksander Nikolaevich, Evgeny Vladimirovich Filippov, Olga Eduardovna Yakovleva, Olga Borisovna Pavlova, Elena Sergeevna Skripkina, Tamila Vitalievna Martynyuk, Irina Fedorovna Bukatova, Anna Viktorovna Tregubova, Dmitry Yurievich Platonov, Tatyana Mikhaylovna Kolomeytseva, Abdullah Al Dalaan, Abeer Abeer Abdelsayed, Ihab Weheba, Sarferaz Saleemi, Hussam Sakkijha, Marcela Bohacekova, Tatiana Valkovicova, Iveta Farkasova, Carlos Andres Quezada, Lucilla Piccari, Isabel Blanco, Laura Sebastian, Antonio Roman, Manuel Lopez, Remedios Otero, Teresa Elias, Luis Jara, Isabel Asencio, Josefa Jiménez Arjona, Raúl Menor Almagro, Salvador López Cárdenas, Salvador Alcaraz García, Patricia Villanueva Rodríguez, Raquel Lopez, Alberto Garcia, Francisco Fernandez Avilés, Sebastian De La Pava, Raquel Yotti, Gregorio Pérez Peñate, Fernando León Marrero, José Manuel Cifrián Martínez, Amaya Martinez-Meñaca, Lecue Pilar Alonso, Sonia Fernandez Rozas, David Iturbe Fernandez, Victor Mora Cuesta, Stefan Söderberg, Sven-Erik Bartfay, Bengt Rundqvist, Monthir Alfetlawi, Peter Wodlin, Esther Irene Schwarz, Rudolf Speich, Frédéric Lador, Thierry Rochat, Paola Gasche-Soccal, Chih-Hsin Hsu, Tsung-Hsien Lin, Ho-Ming Su, Wen-Ter Lai, Chun Yuan Chu, Po-Chao Hsu, Wen-Chol Voon, Hsueh-Wei Yen, Jacob Yih-Jer Wu, Shu-Hao Wu, Wen-Pin Huang, Man-Cai Fong, Chien-Lung Huang, Ping-Hung Kuo, Yen-Hung Lin, Jiunn-Lee Lin, Chi-Sheng Hung, Cho-Kai Wu, Shih-Hsien Sung, Wei-Chun Huang, Chin-Chang Cheng, Shu-Hung Kuo, Wen-Hwa Wang, Wan-Jing Ho, Tsu-Shiu Hsu, Bülent Mutlu, Halil Atas, Gul Ongen, Zeynep Un, Gulfer Okumus, Ismail Hanta, Paul Corris, Andrew Peacock, Colin Church, Mark Toshner, Michael Newnham, Gastroenterology & Hepatology, Pulmonary Medicine, Pulmonary medicine, ACS - Pulmonary hypertension & thrombosis, and VU University medical center
- Subjects
real-world ,pulmonary embolism ,pyrimidines ,MedDRA ,data analysis ,Peripheral edema ,Chronic thromboembolic pulmonary hypertension ,randomized controlled trials as topic ,Clinical practice ,registry ,time factors ,law.invention ,chronic thromboembolic pulmonary hypertension ,0302 clinical medicine ,Randomized controlled trial ,law ,middle aged ,Medicine ,030212 general & internal medicine ,humans ,Hipertensió pulmonar ,pyrazoles ,clinical practice ,aged ,female ,riociguat ,safety ,chronic disease ,hypertension, pulmonary ,male ,multicenter studies as topic ,prospective studies ,recurrence ,treatment outcome ,registries ,medicine.symptom ,Safety ,medicine.drug ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Registry ,hypertension ,pulmonary ,Hypertension, Pulmonary ,Riociguat ,Pulmonary hypertension ,03 medical and health sciences ,Internal medicine ,Adverse effect ,business.industry ,medicine.disease ,Pneumonia ,030228 respiratory system ,Real-world ,Pulmonary hemorrhage ,business - Abstract
Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. Methods: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping riociguat treatment. Primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System Organ Classes version 21.0, collected during routine clinic visits and collated via case report forms. Results: In total, 956 patients with CTEPH were included in the analysis. The most common AEs in these patients were peripheral edema/edema (11.7%), dizziness (7.5%), right ventricular (RV)/cardiac failure (7.7%), and pneumonia (5.0%). The most common SAEs were RV/cardiac failure (7.4%), pneumonia (4.1%), dyspnea (3.6%), and syncope (2.5%). Exposure-adjusted rates of hemoptysis/pulmonary hemorrhage and hypotension were low and comparable to those in the long-term extension study of riociguat (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial [CHEST-2]). Conclusion: Data from EXPERT show that in patients with CTEPH, the safety of riociguat in routine practice was consistent with the known safety profile of the drug, and no new safety concerns were identified. © 2020 The Authors Eli Lilly and Company; Pfizer; Bayer; GlaxoSmithKline; Merck; Actelion Pharmaceuticals; Meso Scale Diagnostics; United Therapeutics Corporation; Novartis Pharma; Merck Sharp and Dohme; GlaxoSmithKline Australia; Deutsche Forschungsgemeinschaft; Grupo Ferrer Internacional, S.A The EXPERT registry was funded by Bayer AG (Berlin, Germany) and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA. The authors acknowledge the database administration by Torsten Tille, Dresden, and the project administration of Mrs Romy Hoppenz and Mrs Linda Kottke at GWT-TUD GmbH, Dresden. Medical writing services provided by Richard Murphy PhD of Adelphi Communications Ltd, Macclesfield, UK were funded by Bayer AG in accordance with Good Publication Practice (GPP3) guidelines. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Prof Marius M. Hoeper reports personal fees from Bayer AG, during the conduct of the study; personal fees from Actelion, personal fees from Acceleron, personal fees from MSD, personal fees from Jansen, personal fees from Pfizer, outside the submitted work. Dr Hans Klose reports speaker and consultancy fees from Actelion, Bayer AG, GSK, Novartis, Pfizer, and United Therapeutics and research support from Actelion, Bayer AG, GSK, Pfizer, and MSD. Dr Michael Halank reports personal fees and non-financial support from Actelion, AstraZeneca, Bayer AG, Berlin-Chemie, GSK, OMT, MSD, and Novartis. Dr George Giannakoulas reports speaker and consultancy fees from Actelion, Bayer, ELPEN Pharmaceuticals, GSK, Pfizer, Lilly, and United Therapeutics, and research support from GSK, ELPEN Pharmaceuticals, and Galenica. Dr Henning Gall has received honoraria and/or other support from Actelion, AstraZeneca, Bayer, BMS, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer, and United Therapeutics. Dr Pavel Jansa reports consultancy and speaker fees from MSD, AOP Orphan, and Actelion. Prof Ekkehard Grünig reports research grants and speaker honoraria/consultancy fees from Actelion and Bayer/MSD, research grants from GSK, United Therapeutics, Bellerophon, OMT GmbH, Pfizer, Reata, and Novartis, and speaker honoraria from Bial, Medscape, and OrPha Swiss GmbH. Prof David Pittrow reports personal fees from Actelion, Bayer AG, Aspen, Boehringer Ingelheim, Sanofi, Biogen, Shire, and MSD outside the submitted work. Silvia Ulrich reports research grants and personal fees from Actelion, Bayer, MSD, and Orpha Swiss. Tobias J. Lange has received personal fees from Actelion, MSD, Pfizer, and OMT orphan. Dr Iraklis Tsangaris reports speaker and consultancy fees from Actelion, Bayer AG, ELPEN, GSK, MSD, Pfizer, and United Therapeutics. Stephan Rosenkranz reports remunerations for lectures and/or consultancy from Abbott, Actelion, Arena, Bayer, Ferrer, GSK, MSD, Novartis, Pfizer, and United Therapeutics; and research support to his institution from Actelion, Bayer, Novartis, Pfizer, and United Therapeutics. Repke J. Snijder reports grants from Pfizer and Actelion Pharmaceuticals. Prof Iveta Šimková reports consultancy and speaker fees from MSD, AOP Orphan, and Actelion. Dr Marc Humbert reports grants and personal fees from Bayer and GSK, and personal fees from Actelion, Merck, and United Therapeutics. Marion Delcroix has received investigator, speaker, consultant, and steering committee member fees from Actelion, Bayer AG, Bellerophon, Eli Lilly, GlaxoSmithKline, MSD, Pfizer, and Reata, and research grants from Actelion. Joan A. Barberà reports receipt of honoraria for consultation or speaker fees from Actelion and Merck; and research support through his institution from Actelion, Merck, GlaxoSmithKline, and Ferrer. Joanna Pepke-Zaba reports research grants and speaker honoraria/consultancy fees from Actelion, Bayer/MSD, and GSK. Jean-Luc Vachiéry reports ongoing consultancies to Actelion, Sonnivie, Arena Pharma, Bial Portela, and Respira Therapeutics, past consultancies to AstraZeneca, BayerShering, CardioMEMS, GlaxoSmithKline, Pfizer, Merck, and United Therapeutics, and current membership of an advisory board or similar group for Actelion and GlaxoSmithKline. Jean-Luc Vachiéry's institution receives funding from Actelion Pharmaceuticals for performing clinical studies. Regina Steringer-Mascherbauer, Jens Klotsche, and Miguel-Angel Gomez Sanchez have no conflicts of interest relevant to the EXPERT study. Hossein-Ardeschir Ghofrani reports personal fees for advisory board work, and payment for lectures including service on speaker bureaus, from Actelion, Bayer, GSK, Novartis, and Pfizer; consultancy fees from Actelion, Bayer, Bellerophon Pulse Technologies, GSK, MSD, Novartis, and Pfizer; and grants from Deutsche Forschungsgemeinschaft (DFG). Pilar Escribano Subias reports personal fees from Actelion, Bayer AG, GlaxoSmithKline, and Merck Sharp & Dohme, and grants from Actelion, Bayer AG, GlaxoSmithKline, and Ferrer, outside the submitted work. Gérald Simonneau reports personal fees and non-financial support from Actelion, personal fees and non-financial support from Bayer, personal fees and non-financial support from MSD, outside the submitted work. Douglas S. Helmersen reports industry-sponsored research with Bayer AG, United Therapeutics, and Gilead Sciences, Inc., and advisory board/speaker fees from Bayer AG and Actelion. David Langleben reports honoraria, consultation fees, research support, and/or travel expenses from Actelion, Arena, Bayer AG, Northern Therapeutics, PhaseBio, Acceleron, Janssen, and United Therapeutics. Anco Boonstra reports consultancy fees from Pfizer BV and hospitality from Teva Nederland. Lisa M. Mielniczuk reports speaker fees and honoraria from Bayer AG, and speaker fees, consultancy fees, and travel fees from Actelion. Evgenia Williams and Christian Meier are employees of Bayer AG.
- Published
- 2021
6. Pain, Swelling and Blue Discoloration of Right Hand in a COVID-19 Patient
- Author
-
Andrey I. Yaroshetskiy, Zamira M. Merzhoeva, Natalia V. Trushenko, Sergey Avdeev, Galia S. Nuralieva, Natalia A. Tsareva, and Galina Nekludova
- Subjects
medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pain ,Article ,Edema ,Epidemiology ,Pandemic ,medicine ,Humans ,Ultrasonography, Doppler, Color ,Pandemics ,Thrombectomy ,Venous Thrombosis ,business.industry ,SARS-CoV-2 ,COVID-19 ,Middle Aged ,medicine.disease ,Hand ,Dermatology ,Venous thrombosis ,Emergency Medicine ,Female ,medicine.symptom ,Swelling ,business - Published
- 2020
7. Lung ultrasound can predict response to the prone position in awake non-intubated patients with COVID‑19 associated acute respiratory distress syndrome
- Author
-
Andrey I. Yaroshetskiy, Natalia A. Tsareva, Natalia V. Trushenko, Djuro Kosanovic, Sergey Avdeev, and Galina Nekludova
- Subjects
Adult ,Male ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,MEDLINE ,Acute respiratory distress ,Critical Care and Intensive Care Medicine ,Patient Positioning ,Russia ,Cohort Studies ,Prone Position ,Research Letter ,Medicine ,Humans ,Prospective Studies ,Lung ,Ultrasonography ,Respiratory Distress Syndrome ,business.industry ,lcsh:Medical emergencies. Critical care. Intensive care. First aid ,COVID-19 ,lcsh:RC86-88.9 ,Middle Aged ,Lung ultrasound ,Prone position ,Emergency medicine ,Female ,business - Published
- 2020
8. Pulmonary hypertension associated with definitive and probable usual interstitial pneumonia
- Author
-
Zhanna Naumenko, Alexander Cherniak, Natalia A. Tsareva, Sergey Avdeev, Galina Nekludova, and Zamira Merhoeva
- Subjects
medicine.medical_specialty ,Usual interstitial pneumonia ,business.industry ,Internal medicine ,Cardiology ,medicine ,medicine.disease ,business ,Pulmonary hypertension - Published
- 2020
9. Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study
- Author
-
Svetlana Yu. Chikina, Andrey I. Yaroshetskiy, Tatiana Yu. Gneusheva, Galia S. Nuralieva, Galina Nekludova, Zamira M. Merzhoeva, Sergey Avdeev, Natalia A. Tsareva, Anna E. Shmidt, Natalia V. Trushenko, and Olga A. Suvorova
- Subjects
Diarrhea ,Male ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,medicine.drug_class ,Short Communication ,medicine.medical_treatment ,Immunology ,Pilot Projects ,Therapeutics ,Cytokine storm ,Antibodies, Monoclonal, Humanized ,Monoclonal antibody ,Severity of Illness Index ,Biochemistry ,law.invention ,Netakimab ,law ,Internal medicine ,medicine ,Humans ,Immunology and Allergy ,Molecular Biology ,Aged ,Retrospective Studies ,Inflammation ,Mechanical ventilation ,Inpatients ,SARS-CoV-2 ,business.industry ,Interleukin-17 ,COVID-19 ,Hematology ,Oxygenation ,Length of Stay ,Middle Aged ,medicine.disease ,Respiration, Artificial ,Intensive care unit ,Pathophysiology ,Hospitalization ,IL-17 ,Dyspnea ,Treatment Outcome ,Case-Control Studies ,Female ,Interleukin 17 ,business - Abstract
Background One of the main pathophysiological mechanisms underlying the severe course of COVID-19 is the hyper-inflammatory syndrome associated with progressive damage of lung tissue and multi-organ dysfunction. IL-17 has been suggested to be involved in hyper-inflammatory syndrome. Objective To evaluate the efficacy and safety of the IL-17 inhibitor netakimab in patients with severe COVID-19. Study design. In our retrospective case-control study we evaluated the efficacy of netakimab in hospitalized patients with severe COVID-19 outside the intensive care unit (ICU). Patients in the experimental group were treated with standard of care therapy and netakimab at a dose of 120 mg subcutaneously. Results 171 patients with severe COVID-19 were enrolled in our study, and 88 of them received netakimab. On the 3 day of therapy, body temperature, SpO2/FiO2, NEWS2 score, and CRP improved significantly in the netakimab group compared to the control group. Other clinical outcomes such as transfer to ICU (11.4% vs 9.6%), need for mechanical ventilation (10.2% vs 9.6%), 28-day mortality (10.2% vs 8.4%), did not differ between the groups. Conclusion In hospitalized patients with severe COVID-19, anti-IL-17 therapy might mitigate the inflammatory response and improve oxygenation, but do not affect the need for mechanical ventilation and mortality.
- Published
- 2021
10. Beneficial effects of inhaled surfactant in patients with COVID-19-associated acute respiratory distress syndrome
- Author
-
Ralph T. Schermuly, Andrey I. Yaroshetskiy, Djuro Kosanovic, Oleg A. Rosenberg, Sergey Avdeev, Zamira M. Merzhoeva, Svetlana Yu. Chikina, Natalia V. Trushenko, Violetta I. Sopova, Natalia A. Tsareva, and Margarita I. Sopova
- Subjects
Male ,Pulmonary and Respiratory Medicine ,ARDS ,medicine.medical_treatment ,Surfactant therapy ,Article ,03 medical and health sciences ,0302 clinical medicine ,Pulmonary surfactant ,Intensive care ,Administration, Inhalation ,Surfactant ,Humans ,Medicine ,Prospective Studies ,030212 general & internal medicine ,Pandemics ,Aged ,Mechanical ventilation ,Respiratory Distress Syndrome ,Acute respiratory distress syndrome ,Inhalation ,SARS-CoV-2 ,business.industry ,COVID-19 ,Pulmonary Surfactants ,Oxygenation ,Middle Aged ,medicine.disease ,Intensive Care Units ,030228 respiratory system ,Case-Control Studies ,Anesthesia ,Breathing ,Female ,business - Abstract
Background We have investigated the use of nebulized surfactant as a potential therapeutic option for the patients with coronavirus disease 2019 (COVID-19)-associated acute respiratory distress syndrome (ARDS) undergoing non-invasive ventilation. Methods The patients were divided into 2 groups: surfactant (n = 33) and control (n = 32). The subjects in the surfactant group received the inhaled surfactant at daily dose of 150–300 mg. The oxygenation parameters and several clinical outcomes were analyzed. Results On the 5 day of therapy, PaO2/FiO2 improved significantly in the surfactant group compared to the control group (184 (155–212) mmHg vs 150 (91–173) mmHg, p = 0.02). The inhaled surfactant significantly reduced the need for transfer of patients to intensive care units (24.2% vs 46.9%, p = 0.05) and invasive mechanical ventilation (18.2% vs 40.6%, p = 0.04). Even more, the nebulized surfactant shortened the length of non-invasive ventilation (7 (3–13) days vs 11 (5–22) days, p = 0.02) and time spent in hospital (18 (16–27) days vs 26 (21–31) days, p = 0.003) in patients suffering from COVID-19-linked ARDS. Conclusions Our preliminary data provided indications that inhaled surfactant therapy may represent a promising option for patients with COVID-19-associated ARDS. However, larger clinical trials are crucially needed.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.